Treatment results of Gemcitabine-Cisplatin induction chemotherapy followed by concurrent chemoradiotherapy in stage III-IVA nasopharyngeal carcinoma at National Cancer Hospital
Main Article Content
Abstract
Nasopharyngeal Carcinoma (NPC) is one of the most common head and neck cancers in Vietnam. For advanced stages, concurrent chemoradiotherapy is the cornerstone treatment with a high rate of local and regional disease control. However, treatment failure is mainly due to distant metastasis, raising the need for additional systemic therapy. While the role of adjuvant chemotherapy remains unclear, induction chemotherapy has shown promising results with better tolerability. This study was conducted on 57 patients with stage III-IVA nasopharyngeal carcinoma treated with an induction chemotherapy regimen of gemcitabine and cisplatin followed by concurrent chemoradiotherapy at Vietnam National Cancer Hospital from 2019 to 2021. The study showed a response rate of 94.8% after induction chemotherapy, with a complete response rate of 86% after treatment. The 1-year and 2-year survival rates were 95.8% and 79.8%, respectively. Few grade ≥ 3 acute and chronic side effects were observed. The study demonstrates that the Gemcitabine-Cisplatin induction chemotherapy regimen followed by concurrent chemoradiotherapy yields a high response rate and good tolerance.
Article Details
Keywords
Nasopharyngeal carcinoma, induction chemotherapy, concurrent chemoradiotherapy, gemcitabine, cisplatin
References
2. Salehiniya H, Mohammadian M, Mohammadian-Hafshejani A, Mahdavifar N. Nasopharyngeal cancer in the world- epidemiology, incidence, mortality and risk factors.
3. Yang SS, Guo JG, Liu JN, et al. Effect of Induction Chemotherapy in Nasopharyngeal Carcinoma: An Updated Meta-Analysis. Front Oncol. 2021; 10:591205. doi:10.3389/fonc.2020.591205.
4. Zhang Y, Chen L, Hu GQ, et al. Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2022; 40(22): 2420-2425. doi:10.1200/JCO.22.00327.
5. Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016; 17(11): 1509-1520. doi:10.1016/S1470-2045(16)30410-7.
6. Jin T, Qin W feng, Jiang F, et al. Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma. Transl Oncol. 2019; 12(4): 633-639. doi:10.1016/j.tranon.2019.01.002.
7. head-and-neck.pdf. Accessed August 2, 2024. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.
8. Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019; 381(12): 1124-1135. doi:10.1056/NEJMoa1905287.
9. Reffai A, Mesmoudi M, Derkaoui T, et al. Epidemiological Profile and Clinicopathological, Therapeutic, and Prognostic Characteristics of Nasopharyngeal Carcinoma in Northern Morocco. Cancer Control J Moffitt Cancer Cent. 2021; 28: 10732748211050587. doi:10.1177/10732748211050587.
10. Xie SH, Yu ITS, Tse LA, Mang OW kong, Yue L. Sex difference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983–2008: Suggestion of a potential protective role of oestrogen. Eur J Cancer. 2013; 49(1):150-155. doi:10.1016/j.ejca.2012.07.004.
11. Trung NQ, Thắng TX, Khanh PĐ, Thảo HT. Đánh giá đáp ứng hoá xạ trị đồng thời ung thư vòm mũi họng tại Bệnh viện Tai Mũi Họng Trung ương. J 108 - Clin Med Phamarcy. Published online May 5, 2023. doi:10.52389/ydls.v18i0.1770.
12. Yang Q, Cao SM, Guo L, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer. 2019; 119:87-96. doi:10.1016/j.ejca.2019.07.007.
13. Li WF, Chen NY, Zhang N, et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial. Int J Cancer. 2019; 145(1):295-305. doi:10.1002/ijc.32099.
14. Pan JJ, Ng WT, Zong JF, et al. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016; 122(4): 546-558. doi:10.1002/cncr.29795.
15. Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016; 17(11): 1509-1520. doi:10.1016/S1470-2045(16)30410-7.
16. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357(17):1695-1704. doi:10.1056/NEJMoa071028.
17. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357(17):1705-1715. doi:10.1056/NEJMoa070956.
18. Đánh giá kết quả bước đầu hoá chất tân bổ trợ phác đồ TCF trên bệnh nhân ung thư vòm giai đoạn III-IVa tại Bệnh viện K – Tạp chí Ung Thư học Việt Nam. Accessed July 13, 2024. https://vnjo.vn/bai-nghien-cuu/danh-gia-ket-qua-buoc-dau-hoa-chat-tan-bo-tro-phac-do-tcf-tren-benh-nhan-ung-thu-vom-giai-doan-iii-iva-tai-benh-vien-k/.
19. Zhu J, Duan B, Shi H, et al. Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma. Oral Oncol. 2019; 97:37-43. doi:10.1016/j.oraloncology.2019.08.001.
20. Chinh HĐ, Tuấn NA, Hà LM, et al. Kết quả bước đầu phác đồ hóa trị dẫn đầu gemcitabin-cisplatin và hóa xạ trị đồng thời ung thư vòm mũi họng giai đoạn III-IVA. J 108 - Clin Med Phamarcy. Published online May 5, 2023. doi:10.52389/ydls.v18i0.1769.
21. Bhide SA, Newbold KL, Harrington KJ, Nutting CM. Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers. Br J Radiol. 2012; 85(1013):487-494. doi:10.1259/bjr/85942136.